FEMY · Femasys Inc.

Femasys Inc. delivered a transformative Q1 2026 with sales increasing 24.5% to $424,889, primarily from FemBloc product sales, signaling early commercial traction in its women's health portfolio. This growth offset ongoing operating losses of $4.2 million, but was more than compensated by $5.1 million in other income, mainly from $3.7 million gain in warrants liabilities fair value and $1.5 million from conversion option liability changes, swinging the company to net income of $846,100 or $0.00 per share, versus a $5.9 million loss or ($0.23) per share in Q1 2025. R&D expenses halved to $1.3 million due to shifting development products to inventory for commercialization and cuts in clinical, compensation, and professional costs. CEO Kathy Lee-Sepsick highlighted acceleration of FemaSeed via FemSperm family for in-office OB/GYN fertility care and progress on FemBloc with FINALE trial enrollment started, plus MDSAP certification and CPT code approval for FemaSeed. Strategic moves included partnerships with AMI Technologies for Israel, OR Consulting for Switzerland, and Refuah Health Center, plus COO John Canning and director Kenneth D. Eichenbaum, M.D. appointments. Balance sheet shows $5.4 million cash, down from $9.3 million at year-end, with $6.1 million inventory up slightly, but liabilities reduced to $9.2 million from $14.9 million via liability fair value gains. Management states cash funds operations into Q3 2026 under current plan, emphasizing global scaling of fertility and non-surgical birth control solutions amid low fertility rates.